ClinicalTrials.gg
CompletedNCT04307381Updated May 8, 2026Results posted

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

A Phase 2 interventional study of Donidalorsen in Hereditary Angioedema, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Enrollment
61st of 74
20 · median 57
Started
2020
with 1 other
Phase 2
16 of 84
1 open now
Registered
45th of 84
by date
Lead sponsor
5 of 84
Ionis Pharmaceuticals, Inc.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 61st largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2020, is one of 16 in phase 2, and was the 45th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).

Read the detailed description

This was an open-label extension study of donidalorsen in 20 participants with HAE. The length of participation in the study was approximately 68 weeks, which included an up to 4-week qualification period, a 52-week treatment period, and a 12-week post-treatment period. Following the Week 53 treatment period visit, participants received donidalorsen in an extended treatment period for up to an additional 156 weeks. Participants taking part in the extended treatment period entered the 12-week post-treatment period after completion of, or early termination from, the extended treatment period.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • Hereditary Angioedema
  • HAE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Satisfactory completion of ISIS 721744-CS2 (index study) through Week 17 with an acceptable safety and tolerability profile, per Sponsor and Investigator judgement
  2. Able and willing to participate in a 64-week study
  3. Females must be non-pregnant, non-lactating and either surgically sterile or
  4. Males must be surgically sterile or abstinent* or if engaged in sexual relations with a female of , participant is utilizing an acceptable method
  5. Participants must have access to, and the ability to use, ≥ 1 acute medication(s) (e.g., plasma-derived or recombinant C1- inhibitor (C1-INH) concentrate or a bradykinin-2 [BK-2] antagonist) to treat angioedema attacks

Exclusion criteria

Exclusion Criteria:

1. Have any new condition or worsening of an existing condition or change or anticipated change in medication, which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    HAE-1/HAE-2

    Participants with hereditary angioedema Type I/Type II (HAE-1/HAE-2) who received placebo or donidalorsen, 80 milligrams (mg), SC once every 4 weeks, in the previous study ISIS 721744-CS2 (NCT04030598), received donidalorsen, 80 mg, SC once every 4 weeks, from Week 1 to Week 13 (Fixed Dosing Period). Starting From Week 17 (Flexible Dosing Period), participants had 3 different dosing options as: 80 mg every 4 weeks, 80 mg every 8 weeks for participants who were attack-free for ≥12 weeks, 100 mg every 4 weeks for participants who were not attack-free for ≥12 weeks up to Week 53 based on the investigator and sponsor medical monitor recommendation. Participants continued flexible dosing from Week 53 for up to approximately 209 weeks.

    Drug: Donidalorsen

  • Experimental
    HAE-nC1-INH

    Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) who received donidalorsen, 80 mg, SC, once every 4 weeks, in the previous study ISIS 721744-CS2 (NCT04030598), continued to receive donidalorsen, 80 mg, SC once every 4 weeks, from Week 1 to Week 13 (Fixed Dosing Period). Starting From Week 17 (Flexible Dosing Period), participants had 2 different dosing options as: 80 mg every 4 weeks, and 100 mg every 4 weeks for participants who were not attack-free for ≥12 weeks up to Week 53 based on the investigator and sponsor medical monitor recommendation. Participants continued flexible dosing from Week 53 for up to approximately 209 weeks.

    Drug: Donidalorsen

Interventions

  • Donidalorsen administered SC

    Also known as: ISIS 721744, IONIS-PKK-LRx

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the AE is considered related to the medicinal (investigational) product. TEAEs were defined as those AEs that either started or worsened in severity on or after the date/time of first administration of study drug in this OLE Study. TEAEs included both serious and non-serious TEAEs.

    Time frame: Up to Week 221

  2. Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments

    Clinical laboratory tests including clinical chemistry, hematology, coagulation, complement, inflammatory, urinalysis were performed. The percentage of participants with clinically meaningful changes were reported. Clinical meaningfulness was determined by the investigator.

    Time frame: Up to Week 221

  3. Percentage of Participants With Clinically Meaningful Changes in Vital Signs

    Vital sign measurements including heart rate, respiratory rate, body temperature, systolic and diastolic blood pressure and pulse pressure were assessed. Percentage of participants with clinically meaningful changes in the vital signs were reported. Clinically meaningfulness was determined by the investigator.

    Time frame: Up to Week 221

  4. Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters

    The ECG parameters included ventricular rate, PR interval, QRS duration, QTc, QT corrected using the Fridericia's formula (QTcF), QT corrected using the Bazett's formula (QTcB), and overall interpretation. Percentage of participants with clinically meaningful changes in the ECG parameters were reported. Clinical meaningfulness was determined by the investigator.

    Time frame: Up to Week 221

  5. Percentage of Participants Who Received At Least One Concomitant Medication

    Concomitant medications include medications that participants were exposed to on or after the first dose of ISIS 721744 in the OLE study. Percentage of participants who received at least one concomitant medication were reported.

    Time frame: Up to Week 221

Secondary outcomes

  1. Percent Change From Baseline in Time-normalized HAE Attack (Per 4 Weeks) Rate

    HAE attack rate was calculated for each participant as the number of HAE attacks occurring during the respective period divided by the number of days the participant contributed to this period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). A negative change from baseline in HAE attacks indicates an improvement in HAE attacks.

    Time frame: Up to Week 221

  2. Percentage of Participants Who Used On-demand Medications

    The most commonly used on-demand medications during the On-Treatment Period were C1 esterase inhibitors (human) and icatibant, which were allowed per-protocol for treatment of acute attacks.

    Time frame: Up to Week 221

07

Results

Posted May 8, 2026

Participant flow

Participants took part in the study from 31 March 2020 to 24 January 2025.

Participant flow — Overall Study
MilestoneHAE-1/HAE-2HAE-nC1-INH
Started173
Flexible-dose period: hae-1/hae-2 (donidalorsen 80 mg every 4 weeks)130
Flexible-dose period: hae-1/hae-2 (donidalorsen 80 mg every 8 weeks)80
Flexible-dose period: hae-1/hae-2 (donidalorsen 100 mg every 4 weeks)10
Flexible-dose period: hae-nc1-inh (donidalorsen 80 mg every 4 weeks)01
Flexible-dose period: hae-nc1-inh (donidalorsen 100 mg every 4 weeks)02
Completed162
Not completed11
Withdrew: Voluntary withdrawal11

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the AE is considered related to the medicinal (investigational) product. TEAEs were defined as those AEs that either started or worsened in severity on or after the date/time of first administration of study drug in this OLE Study. TEAEs included both serious and non-serious TEAEs.

Time frame:
Up to Week 221
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)70.666.784.662.5100100100
PrimaryPercentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments

Clinical laboratory tests including clinical chemistry, hematology, coagulation, complement, inflammatory, urinalysis were performed. The percentage of participants with clinically meaningful changes were reported. Clinical meaningfulness was determined by the investigator.

Time frame:
Up to Week 221
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments
percentage of participantsFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments0000000
PrimaryPercentage of Participants With Clinically Meaningful Changes in Vital Signs

Vital sign measurements including heart rate, respiratory rate, body temperature, systolic and diastolic blood pressure and pulse pressure were assessed. Percentage of participants with clinically meaningful changes in the vital signs were reported. Clinically meaningfulness was determined by the investigator.

Time frame:
Up to Week 221
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Meaningful Changes in Vital Signs
percentage of participantsFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
Percentage of Participants With Clinically Meaningful Changes in Vital Signs0000000
PrimaryPercentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters

The ECG parameters included ventricular rate, PR interval, QRS duration, QTc, QT corrected using the Fridericia's formula (QTcF), QT corrected using the Bazett's formula (QTcB), and overall interpretation. Percentage of participants with clinically meaningful changes in the ECG parameters were reported. Clinical meaningfulness was determined by the investigator.

Time frame:
Up to Week 221
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters
percentage of participantsFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters0000000
PrimaryPercentage of Participants Who Received At Least One Concomitant Medication

Concomitant medications include medications that participants were exposed to on or after the first dose of ISIS 721744 in the OLE study. Percentage of participants who received at least one concomitant medication were reported.

Time frame:
Up to Week 221
Reported as:
Number · percentage of participants
Percentage of Participants Who Received At Least One Concomitant Medication
percentage of participantsHAE-1/HAE-2HAE-nC1-INH
Percentage of Participants Who Received At Least One Concomitant Medication100100
SecondaryPercent Change From Baseline in Time-normalized HAE Attack (Per 4 Weeks) Rate

HAE attack rate was calculated for each participant as the number of HAE attacks occurring during the respective period divided by the number of days the participant contributed to this period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). A negative change from baseline in HAE attacks indicates an improvement in HAE attacks.

Time frame:
Up to Week 221
Reported as:
Mean · percent change
Percent Change From Baseline in Time-normalized HAE Attack (Per 4 Weeks) Rate
percent changeFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
Percent Change From Baseline in Time-normalized HAE Attack (Per 4 Weeks) Rate-94.41 ± 10.260-60.82 ± 19.310-97.21 ± 5.672-82.70 ± 35.598-95.16 ± NA-87.21 ± NA-64.04 ± 30.597
SecondaryPercentage of Participants Who Used On-demand Medications

The most commonly used on-demand medications during the On-Treatment Period were C1 esterase inhibitors (human) and icatibant, which were allowed per-protocol for treatment of acute attacks.

Time frame:
Up to Week 221
Reported as:
Number · percentage of participants
Percentage of Participants Who Used On-demand Medications
percentage of participantsFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
By the End of Fixed Dosing Period (Week 17)11.866.7—————
By the End of Flexible Dosing Period (Week 209)——38.562.5100100100

Adverse events

Collected over Up to Week 221. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fixed-dose Period: HAE-1/HAE-20/17 (0%)0/17 (0%)12/17 (70.6%)
Fixed-dose Period: HAE-nC1-INH0/3 (0%)0/3 (0%)2/3 (66.7%)
Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)0/13 (0%)0/13 (0%)11/13 (84.6%)
Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)0/8 (0%)0/8 (0%)5/8 (62.5%)
Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)0/1 (0%)0/1 (0%)1/1 (100%)
Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)0/1 (0%)1/1 (100%)1/1 (100%)
Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/170/30/130/80/11/10/2
Most frequent other events
Showing 10 of 119
Most frequent other events
EventFixed-dose Period: HAE-1/HAE-2Fixed-dose Period: HAE-nC1-INHFlexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks)Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks)Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks)
COVID-19Infections and infestations2/170/35/133/80/11/11/2
Urinary tract infectionInfections and infestations0/171/32/131/81/10/10/2
AnxietyPsychiatric disorders0/170/32/130/80/11/11/2
Emotional distressPsychiatric disorders0/170/30/130/80/11/10/2
VomitingGastrointestinal disorders1/170/30/130/81/10/10/2
Viral infectionInfections and infestations0/170/30/130/81/10/10/2
DyspepsiaGastrointestinal disorders0/170/30/130/81/10/10/2
Injection site discolourationGeneral disorders0/170/31/131/81/10/10/2
Injection site indurationGeneral disorders0/170/30/130/81/10/10/2
CoughRespiratory, thoracic and mediastinal disorders0/170/32/130/81/10/10/2

Baseline characteristics

The safety population included all enrolled participants who received at least 1 dose in the open-label extension (OLE) study.

Age, Continuous
Age, Continuous(years)HAE-1/HAE-2HAE-nC1-INHTotal
Mean38.9 ± 14.6834.3 ± 8.3338.3 ± 13.84
Sex: Female, Male
Sex: Female, Male(Participants)HAE-1/HAE-2HAE-nC1-INHTotal
Female11314
Male606
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HAE-1/HAE-2HAE-nC1-INHTotal
Hispanic or Latino101
Not Hispanic or Latino16319
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HAE-1/HAE-2HAE-nC1-INHTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White16319
More than one race000
Unknown or Not Reported000
08

Study locations

7 sites
  • Ionis Investigative Site
    Scottsdale, Arizona 85251, United States
  • Ionis Investigative Site
    Santa Monica, California 90404, United States
  • Ionis Investigative Site
    Plymouth, Minnesota 55446, United States
  • Ionis Investigative Site
    Cincinnati, Ohio 45231, United States
  • Ionis Investigative Site
    Hershey, Pennsylvania 17033, United States
  • Ionis Investigative Site
    Dallas, Texas 75231, United States
  • Ionis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
09

References and documents

Publications

  • Manning ME, de Lange M, Bernstein JA, Craig T, Lumry WR, Raasch J, Tachdjian R, Bordone L, Deng Y, Newman KB, Cohn DM. Donidalorsen for hereditary angioedema: Long-term results from a 4-year, phase 2, open-label extension study. Ann Allergy Asthma Immunol. 2026 Jun;136(6):699-705.e1. doi: 10.1016/j.anai.2026.02.019. Epub 2026 Mar 7. PubMed 41802598 ↗
  • Petersen RS, Bordone L, Riedl MA, Tachdjian R, Craig TJ, Lumry WR, Manning ME, Bernstein JA, Raasch J, Zuraw BL, Deng Y, Newman KB, Alexander VJ, Lui C, Schneider E, Cohn DM. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. Allergy. 2024 Mar;79(3):724-734. doi: 10.1111/all.15948. Epub 2023 Nov 27. PubMed 38009241 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jan 2025, 57 months.

Results were first posted in May 2026, 1 year 3 months after primary completion. A results delay was requested in Jan 2026.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2020
First posted
Mar 13, 2020
StartActual
Mar 31, 2020
Primary completionActual
Jan 24, 2025
CompletionActual
Jan 24, 2025
Results delay requested
Jan 23, 2026
Results first posted
May 8, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04307381
Responsible party
Sponsor
First posted
Mar 13, 2020
Start date
Mar 31, 2020
Primary completion
Jan 24, 2025
Completion
Jan 24, 2025
Results posted
May 8, 2026
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donidalorsen

Start the discussion